Cortechs.ai | Cortechs.ai announces NeuroQuant® support of Toshiba Titan 3T MRI scanner

Cortechs.ai announces NeuroQuant® support of Toshiba Titan 3T MRI scanner

Cortechs.ai increases physician access to volumetric MRI Processing with additional scanner option.

(SAN DIEGO) Nov. 19, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that Toshiba Titan 3T MRI scanners are now supported by NeuroQuant®, the foremost medical device software for volumetric MRI processing. Cortechs.ai validated the Toshiba Titan 3T MRI scanners with MPower v3.5 to ensure accurate and consistent brain segmentation results.

This new capability provides hospitals, clinics, imaging and research centers worldwide with expanded MRI scanner options when looking to use NeuroQuant to automatically measure brain structures through 3D T1 MRI images. NeuroQuant, the first FDA cleared and CE marked software for measuring brain volumes and assessing brain atrophy, is used in the assessment of neurodegeneration, such as Alzheimer’s disease, epilepsy, multiple sclerosis, as well as, brain volume changes caused by brain trauma.

“We are excited to grow our MRI scanner options to include Toshiba Titan 3T MRI scanners, which is another step in our continuous improvement process to increase access to our capabilities,” said Guri Stark, Cortechs.ai’ CEO. “This expansion strengthens our goal of providing a vendor neutral product, allowing physicians and clinicians more freedom in MRI scanner choices when using NeuroQuant in their assessment of neurodegeneration.”

For more information about using NeuroQuant in Toshiba Titan 3T MRI scanners, please visit Cortechs.ai at Booth 1861 (Hall A, South) during Radiological Society of North America’s (RSNA) 2015 Annual Meeting (Nov. 29 – Dec. 4, McCormick Place, Chicago).

About Cortechs.ai

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.  As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.

More Resources

06/16/2025

Seeing Alzheimer’s More Clearly: How PET Imaging Is Changing the Game

PET imaging is transforming how we detect and monitor Alzheimer’s disease, enabling earlier diagnosis, better disease tracking, and more personalized treatment.

06/11/2025

Cortechs.ai and RMS Medical Devices Forge Distribution Partnership to Expand Access to AI-Powered Imaging Solutions in the Benelux Region

We’re excited to announce our new partnership with RMS Medical Devices to our advanced neuroimaging and prostate imaging solutions to the Benelux region

06/04/2025

Cortechs.ai and deepc Announce Strategic Partnership to Advance AI Integration in Radiology

Press Release: Delivering Clinically Validated AI Solutions for Enhanced Imaging Precision and Workflow Efficiency

05/29/2025

Enhancing Imaging Workflow with DICOM SR: NeuroQuant®’s Seamless Integration 

As imaging becomes more data-driven, tools like NeuroQuant® with DICOM SR support pave the way for smarter, more connected radiology

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.
Scroll to Top